157 related articles for article (PubMed ID: 28293630)
1. Metabolomic Biomarker Identification in Presence of Outliers and Missing Values.
Kumar N; Hoque MA; Shahjaman M; Islam SM; Mollah MN
Biomed Res Int; 2017; 2017():2437608. PubMed ID: 28293630
[TBL] [Abstract][Full Text] [Related]
2. rMisbeta: A robust missing value imputation approach in transcriptomics and metabolomics data.
Shahjaman M; Rahman MR; Islam T; Auwul MR; Moni MA; Mollah MNH
Comput Biol Med; 2021 Nov; 138():104911. PubMed ID: 34634637
[TBL] [Abstract][Full Text] [Related]
3. A novel analysis method for biomarker identification based on horizontal relationship: identifying potential biomarkers from large-scale hepatocellular carcinoma metabolomics data.
Su B; Luo P; Yang Z; Yu P; Li Z; Yin P; Zhou L; Fan J; Huang X; Lin X; Qiao Y; Xu G
Anal Bioanal Chem; 2019 Sep; 411(24):6377-6386. PubMed ID: 31384984
[TBL] [Abstract][Full Text] [Related]
4. Kernel weighted least square approach for imputing missing values of metabolomics data.
Kumar N; Hoque MA; Sugimoto M
Sci Rep; 2021 May; 11(1):11108. PubMed ID: 34045614
[TBL] [Abstract][Full Text] [Related]
5. A Computational Selection of Metabolite Biomarkers Using Emerging Pattern Mining: A Case Study in Human Hepatocellular Carcinoma.
Poezevara G; Lozano S; Cuissart B; Bureau R; Bureau P; Croixmarie V; Vayer P; Lepailleur A
J Proteome Res; 2017 Jun; 16(6):2240-2249. PubMed ID: 28447453
[TBL] [Abstract][Full Text] [Related]
6. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry.
Wu H; Xue R; Dong L; Liu T; Deng C; Zeng H; Shen X
Anal Chim Acta; 2009 Aug; 648(1):98-104. PubMed ID: 19616694
[TBL] [Abstract][Full Text] [Related]
7. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review.
Kimhofer T; Fye H; Taylor-Robinson S; Thursz M; Holmes E
Br J Cancer; 2015 Mar; 112(7):1141-56. PubMed ID: 25826224
[TBL] [Abstract][Full Text] [Related]
8. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery.
Shao Y; Zhu B; Zheng R; Zhao X; Yin P; Lu X; Jiao B; Xu G; Yao Z
J Proteome Res; 2015 Feb; 14(2):906-16. PubMed ID: 25483141
[TBL] [Abstract][Full Text] [Related]
9. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma.
Wang X; Zhang A; Sun H
Hepatology; 2013 May; 57(5):2072-7. PubMed ID: 23150189
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic Characterization Analysis of Human Hepatocarcinoma by Urine Metabolomics Approach.
Liang Q; Liu H; Wang C; Li B
Sci Rep; 2016 Jan; 6():19763. PubMed ID: 26805550
[TBL] [Abstract][Full Text] [Related]
11. Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.
De Matteis S; Ragusa A; Marisi G; De Domenico S; Casadei Gardini A; Bonafè M; Giudetti AM
Oxid Med Cell Longev; 2018; 2018():7512159. PubMed ID: 30524660
[TBL] [Abstract][Full Text] [Related]
12. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
[TBL] [Abstract][Full Text] [Related]
13. A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors.
Reis H; Pütter C; Megger DA; Bracht T; Weber F; Hoffmann AC; Bertram S; Wohlschläger J; Hagemann S; Eisenacher M; Scherag A; Schlaak JF; Canbay A; Meyer HE; Sitek B; Baba HA
Biochim Biophys Acta; 2015 Jun; 1854(6):641-50. PubMed ID: 25448011
[TBL] [Abstract][Full Text] [Related]
14. dBMHCC: A comprehensive hepatocellular carcinoma (HCC) biomarker database provides a reliable prediction system for novel HCC phosphorylated biomarkers.
Chu YW; Chien CH; Sung MI; Chen CW; Chen YT
PLoS One; 2020; 15(6):e0234084. PubMed ID: 32497121
[TBL] [Abstract][Full Text] [Related]
15. Metabolomics study of hepatocellular carcinoma: discovery and validation of serum potential biomarkers by using capillary electrophoresis-mass spectrometry.
Zeng J; Yin P; Tan Y; Dong L; Hu C; Huang Q; Lu X; Wang H; Xu G
J Proteome Res; 2014 Jul; 13(7):3420-31. PubMed ID: 24853826
[TBL] [Abstract][Full Text] [Related]
16. Robust volcano plot: identification of differential metabolites in the presence of outliers.
Kumar N; Hoque MA; Sugimoto M
BMC Bioinformatics; 2018 Apr; 19(1):128. PubMed ID: 29642836
[TBL] [Abstract][Full Text] [Related]
17. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry.
Chen S; Kong H; Lu X; Li Y; Yin P; Zeng Z; Xu G
Anal Chem; 2013 Sep; 85(17):8326-33. PubMed ID: 23889541
[TBL] [Abstract][Full Text] [Related]
18. High-dimensional biology to comprehend hepatocellular carcinoma.
Vivekanandan P; Singh OV
Expert Rev Proteomics; 2008 Feb; 5(1):45-60. PubMed ID: 18282123
[TBL] [Abstract][Full Text] [Related]
19. Counting missing values in a metabolite-intensity data set for measuring the analytical performance of a metabolomics platform.
Huan T; Li L
Anal Chem; 2015 Jan; 87(2):1306-13. PubMed ID: 25496403
[TBL] [Abstract][Full Text] [Related]
20. 1H-NMR-based metabolomics reveals the biomarker panel and molecular mechanism of hepatocellular carcinoma progression.
Wang KX; Du GH; Qin XM; Gao L
Anal Bioanal Chem; 2022 Feb; 414(4):1525-1537. PubMed ID: 35024914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
